Tvardi Therapeutics, Inc. (TVRD): Nasdaq/NYSE listing notice — Cara Therapeutics receives Nasdaq non-compliance notice for bid price below $1.00 per share

Tvardi Therapeutics, Inc.

Nasdaq notified Cara on Feb 1, 2024 that its common stock bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until July 30, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by July 30, Cara may transfer to Nasdaq Capital Market for an additional 180-day cure period.
Failure to regain compliance could result in delisting from The Nasdaq Global Select Market.
Cara intends to monitor its stock price and consider available options, but no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tvardi Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 1, 2024, Cara Therapeutics, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 30, 2024, to regain compliance with the minimum bid price requirement. To regain com

View on SEC.gov

Browse all listing & compliance notices →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-010123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.